Innovative Drug Solutions for Difficult‑to‑Express and Complex Proteins

Innovative Drug Solutions for Difficult‑to‑Express and Complex Proteins
Product Description

Integrated development and manufacturing solutions combining molecular engineering, vector optimization, host cell engineering, and customized process development. The platform delivers high titers for mAb production, and DTEasy™ strategies have demonstrated significant yield improvements across various difficult‑to‑express protein types. Covers upstream/downstream process development and GMP manufacturing support.

Canton Biologics

  • Country/Region:
    Hong Kong
  • Founded:
    2016
  • On CPHI since:
    2026
  • Employees:
    250 - 499
Company types
CMO/CDMO
Specifications
  • CAS Registry Number
    N/A
  • Details
    Monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), fusion proteins, recombinant proteins; mammalian (CHO) and microbial expression systems; addresses challenges such as low expression, instability, aggregation, and cellular stress.

  • Selling Points
    Proprietary DTEasy™ toolbox; high‑performance CHOzen® host; supports from early R&D to commercial production.

  • Model
    DTEasy™ Toolbox + CHOzen® Expression Platform
  • Supplied from
    China
  • Measured In
    Container

Canton Biologics

  • Country/Region:
    Hong Kong
  • Founded:
    2016
  • On CPHI since:
    2026
  • Employees:
    250 - 499
Company types
CMO/CDMO

More Products from Canton Biologics (2)

  • Biologics Development Solutions for Companion Animal Therapeutics

    Product Biologics Development Solutions for Companion Animal Therapeutics

    Leverages advanced expression technologies, optimised vectors, and flexible bioprocessing platforms to deliver scalable and cost‑efficient solutions tailored to companion animal biologics. Supports from early development to GMP manufacturing, with customisation for veterinary specific requirements.

  • Biomedical and Healthcare Recombinant Protein Solutions

    Product Biomedical and Healthcare Recombinant Protein Solutions

    Combines molecular engineering, host cell optimisation, expression system development, and process optimisation to address complex protein structures. The IgMax® platform enables production of pentameric IgM at high expression levels, with near‑complete pentamer assembly and excellent purity after downstre...